Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) filed this Form 8-K on April 4, 2025, to report the results of a Special Meeting of Stockholders held on the same date. The company is incorporated in Delaware and is headquartered in Bedminster, New Jersey.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting outcomes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Shareholders representing 2,669,608 shares (52.47% of outstanding common stock as of the February 10, 2025 record date) participated in the Special Meeting. Three proposals were approved:
- Proposal 1 (Equity Issuance): Approved the issuance of up to 16,894,212 shares of common stock upon conversion of Series C Convertible Preferred Stock and exercise of warrants to comply with NYSE American listing rules. This may constitute a "Change of Control."
- For: 928,481 votes (88%)
- Against: 127,055 votes (12%)
- Abstain: 3,304 votes
- Broker Non-Votes: 1,610,768
- Proposal 2 (Auditor Ratification): Ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- For: 2,541,613 votes (95%)
- Against: 123,403 votes (5%)
- Abstain: 4,592 votes
- Proposal 3 (Adjournment): Approved a proposal to adjourn the meeting if necessary to solicit additional proxies.
- For: 2,402,119 votes (90%)
- Against: 263,930 votes (10%)
- Abstain: 3,559 votes
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this document, other than the potential dilution associated with the approved issuance of shares under Proposal 1.
Investor Verification Checklist
- Verify the definitive proxy statement filed on March 3, 2025, for detailed terms regarding the Series C Convertible Preferred Stock conversion.
- Confirm the impact of the 16,894,212 potential new shares on existing shareholder dilution and the company's capital structure.
- Review the company's subsequent filings for the actual execution of the share issuance and any related cash proceeds.
- Monitor the company's financial health in upcoming 10-Q or 10-K filings, as this 8-K contains no financial data.